Moreover, the PD-L1 IHC assay is affected by a multitude of technical issues (e.g., companion tests are not equivalent in terms of antibodies and cut-offs; the way to interpret it pathologically, whether on tumor cells or immune cells, is diverse) with difficulties in interpretation and standardization of results across studies (40). The gene discussed is CD274; the disease is neoplasm.